Abbott's HIV Therapy Kaletra Gets Once-Daily Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
A once-daily dosing regimen of 800 mg lopinavir/200 mg ritonavir for treatment-naïve patients is approved based on two clinical trials comparing once- and twice-daily regimens in HIV-1 infected patients. Once-daily administration is not recommended for treatment-experienced patients, labeling states.